|
Pediatric Kidney Transplant without Calcineurin Inhibitors Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Pediatric Kidney Transplant without Calcineurin Inhibitors conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Pediatric Kidney Transplant without Calcineurin Inhibitors Clinical research trials and Pediatric Kidney Transplant without Calcineurin Inhibitors medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Pediatric Kidney Transplant without Calcineurin Inhibitors. Pediatric Kidney Transplant without Calcineurin Inhibitors Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Pediatric Kidney Transplant without Calcineurin Inhibitors clinical trial. Participants frequently get the best healthcare available for their Pediatric Kidney Transplant without Calcineurin Inhibitors condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Pediatric Kidney Transplant without Calcineurin Inhibitors  Pediatric Kidney Transplant without Calcineurin Inhibitors
Pediatric Kidney Transplant without Calcineurin Inhibitors
For Condition: End-Stage Renal Disease
Status: Recruiting
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: The purpose of this study is to see the effect of using drugs other than calcineurin inhibitors to improve the rate of kidney transplant failure. Kidney transplantation can help children with end-stage kidney disease. However, it has been difficult to find treatment for donor graft rejection that does not have a lot of side effects. Researchers hope to find treatments (immunosuppressants) with fewer side effects. One approach is to avoid using calcineurin inhibitors and to try a new drug known as sirolimus instead. Another is to use steroids less often. This study will test whether using sirolimus, fewer steroid treatments, MMF, and certain antibodies will improve long-term graft survival in children receiving kidney transplants from living donors.
Details: Renal transplantation is widely recognized as the treatment of choice for children with end-stage renal disease (ESRD). Although outcomes of renal transplantation in children have improved during the past decade, success has been limited by both non-specific tolerance and the complications associated with immunosuppressants. Steroids and calcineurin inhibitors have the most toxic side effects. Use of sirolimus for immunosuppression has not been associated with as many complications. Recent studies from Europe have demonstrated that sirolimus can be combined with MMF and steroids to provide excellent graft survival in the absence of calcineurin inhibitors. Steroid side-effects can be lessened by tapering the steroid dose to an every-other-day schedule. This protocol tests whether immunosuppression by IL-2r antibody, sirolimus, MMF, and alternate-day steroids will provide comparable graft survival for living donor recipients, compared to current immunosuppression, but with reduced complications of calcineurin inhibitors. Evaluations prior to transplantation include a complete history and physical examination, CBC, liver function tests, and antibodies for CMV, EBV, HIV, HbsAG, and HCV. All appropriate vaccinations are provided before transplantation. Transplant recipients receive immunosuppression therapy using antibody induction (daclizumab), corticosteroids, mycophenolate mofetil, and sirolimus. Serum sirolimus levels are measured so that doses can be adjusted to maintain certain blood levels of the drug. Bactrim and ganciclovir are given for infection prophylaxis. If the patient has consistent high levels of fasting cholesterol, treatment with lipitor may be given. A transplant biopsy is performed at the time of the transplant and at 3, 6, and 12 months post transplantation and at times when a rejection is suspected. A radionuclide GFR is done at the same time points, and at 1, 24, and 36 months. The protocol biopsies, blood, and urine samples will be analyzed by genomic methods to determine differences in gene expression post transplantation. In the event of a first acute rejection, patients are treated with Solu-Medrol for 3 consecutive days. A second rejection (at the discretion of the transplant center) or severe rejection (Banff Grade 3) is treated with antibody therapy and, after a second or severe rejection, the immunosuppressant regimen is changed. Patients are followed for 36 months with routine physical examinations and laboratory assessments.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /21 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients may be eligible for this study if they: - Are 21 years of age and under. - Are kidney recipients of living-donor grafts, except when living-donor grafts are identically matched. Exclusion Criteria Patients will not be eligible for this study if they: - Are recipients of identical (HLA matched) living-donor grafts. - Are recipients of cadaver-donor grafts. - Have certain abnormal kidney diseases that may return. - Have failed 2 or more previous kidney transplants. - Have fat abnormalities that are inherited or present at high levels.
Total Enrollment: 35
Location and Contact Information:
Lauren Schenker *Recruiting*
Rockville, Maryland, 20850
United States
Recruiting
Additional Information:
Study ID Numbers: DAIT CN01; CN01
Study Start Date:
Record last reviewed: September 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00023231
Other End-Stage Renal Disease Studies:
1. A Study to Compare Treatment with Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant
2. End- Stage Renal Disease – High Risk Transplant Recipients
3. Prevention of Kidney Transplant Rejection
4. Steroid Withdrawal in Pediatric Kidney Transplant Recipients
5. Pediatric Kidney Transplant without Calcineurin Inhibitors
Related Studies:
Other End-Stage Renal Disease Clinical Trials
Other Maryland Clinical Trials
Other Rockville Clinical Trials
Pediatric Kidney Transplant without Calcineurin Inhibitors
|
|
|
|
|
|
|
|
